Industry’s Flagship Forum Capturing Advancements Across Discovery, Preclinical, Translational, Clinical & Regulatory Development of Innovative Neuropsychiatric Therapeutics

Uniting 150+ discovery, preclinical, translational, clinical, and regulatory leaders, the 8th Neuropsychiatric Drug Development Summit returns to provide you with an unrivaled opportunity to stay attuned to the latest progress while tackling industry’s most pressing challenges across a wide spectrum of mental health indications.

Recognized by key leaders as the “ideal size”, offering a “targeted audience” perfect for meaningful networking and collaboration, join thought leaders from Bristol Myers Squibb, AbbVie, Otsuka, Johnson & Johnson, Biogen, Lundbeck, Delix Therapeutics, Boehringer Ingelheim, and many more this September to revitalize the mental health drug development landscape.

Over the 3 day agenda, you’ll engage in deep-dive interactive workshops, roundtable discussions, data-driven presentations and structured networking activities to foster collaboration and gain the latest insights to truly advance your pipeline of next generation neuropsychiatric therapeutics.

Our attendees span discovery, in vivo pharmacology, translational medicine, clinical development, medical, regulatory affairs, academics, venture capitalists, and solution providers, ensuring that whatever part you play in transforming the mental health treatment and therapeutic landscape, you are surrounded by peers with the knowledge and capacity to support you.

When you join the Neuropsychiatric Drug Development Summit you can expect to:

• Decipher the journey to ‘precision psychiatry’ through investigating the most progressive advancements in EEG and fluid-based markers
• Discover innovative strategies to control placebo responses and bridge the translational gap to effectively analyze phenotypic behavior preclinically
• Investigate the efficacy of standalone psychedelics vs when applied in conjunction with psychotherapy, and explore groundbreaking progress in novel non-hallucinogenic neuroplastogens
• Review the latest advancements in new targets and mechanisms, including moving beyond atypical antidepressants and antipsychotics, to truly transform patient burdens

Plus, all new for 2025 is the EEG Focus Day which will support your efforts in utilizing EEG as a comprehensive and translational tool to guide your program through end-to-end development, and the new Investor’s Panel which will explore the catalysts driving deal-making momentum in the current neuropsychiatric and mental health R&D landscape.

So, what are you waiting for? Learn more about the summit today and explore the 40+ leading experts presenting at this year’s meeting, the array of sessions and bespoke workshops designed to support you, and the companies attending to advance neuropsychiatric therapeutics.

View the brochure now for all this and more: https://ter.li/g4f9aj